Acorah Software Products - Accounts Production 19.3.600 false true true 31 March 2025 1 April 2024 false 1 April 2025 31 March 2026 31 March 2026 09946000 Dr Benjamin Cobb Dr John Clarkson Dr Simon Douglas iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 09946000 2025-03-31 09946000 2026-03-31 09946000 2025-04-01 2026-03-31 09946000 frs-core:CurrentFinancialInstruments 2026-03-31 09946000 frs-core:Non-currentFinancialInstruments 2026-03-31 09946000 frs-core:BetweenOneFiveYears 2026-03-31 09946000 frs-core:PlantMachinery 2026-03-31 09946000 frs-core:PlantMachinery 2025-04-01 2026-03-31 09946000 frs-core:PlantMachinery 2025-03-31 09946000 frs-core:WithinOneYear 2026-03-31 09946000 frs-core:SharePremium 2026-03-31 09946000 frs-core:ShareCapital 2026-03-31 09946000 frs-core:RetainedEarningsAccumulatedLosses 2026-03-31 09946000 frs-bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 09946000 frs-bus:FilletedAccounts 2025-04-01 2026-03-31 09946000 frs-bus:SmallEntities 2025-04-01 2026-03-31 09946000 frs-bus:AuditExempt-NoAccountantsReport 2025-04-01 2026-03-31 09946000 frs-bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 09946000 frs-bus:Director1 2025-04-01 2026-03-31 09946000 frs-bus:Director2 2025-04-01 2026-03-31 09946000 frs-bus:Director3 2025-04-01 2026-03-31 09946000 frs-countries:EnglandWales 2025-04-01 2026-03-31 09946000 2024-03-31 09946000 2025-03-31 09946000 2024-04-01 2025-03-31 09946000 frs-core:CurrentFinancialInstruments 2025-03-31 09946000 frs-core:Non-currentFinancialInstruments 2025-03-31 09946000 frs-core:BetweenOneFiveYears 2025-03-31 09946000 frs-core:WithinOneYear 2025-03-31 09946000 frs-core:SharePremium 2025-03-31 09946000 frs-core:ShareCapital 2025-03-31 09946000 frs-core:RetainedEarningsAccumulatedLosses 2025-03-31
Registered number: 09946000
Readygo Diagnostics Limited
Unaudited Financial Statements
For The Year Ended 31 March 2026
Contents
Page
Statement of Financial Position 1—2
Notes to the Financial Statements 3—6
Page 1
Statement of Financial Position
Registered number: 09946000
2026 2025
Notes £ £ £ £
FIXED ASSETS
Tangible Assets 4 30,295 45,292
30,295 45,292
CURRENT ASSETS
Debtors 5 384,628 453,811
Cash at bank and in hand 302,887 277,046
687,515 730,857
Creditors: Amounts Falling Due Within One Year 6 (261,796 ) (256,467 )
NET CURRENT ASSETS (LIABILITIES) 425,719 474,390
TOTAL ASSETS LESS CURRENT LIABILITIES 456,014 519,682
Creditors: Amounts Falling Due After More Than One Year 7 (1,049,654 ) -
NET (LIABILITIES)/ASSETS (593,640 ) 519,682
CAPITAL AND RESERVES
Called up share capital 8 7,573 7,573
Share premium account 3,997,819 3,997,819
Income Statement (4,599,032 ) (3,485,710 )
SHAREHOLDERS' FUNDS (593,640) 519,682
Page 1
Page 2
For the year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Income Statement.
On behalf of the board
Dr Simon Douglas
Director
11/08/2026
The notes on pages 3 to 6 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Readygo Diagnostics Limited is a private company, limited by shares, incorporated in England & Wales, registered number 09946000 . The registered office is The Exchange, Colworth Science Park, Sharnbrook, Bedfordshire, MK44 1LQ.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Going Concern Disclosure
The financial statements have been prepared on a going concern basis.
The Company is currently part way through its investment cycle and has a track record of successfully drawing down investment funds. The Directors are confident that the necessary funding will be secured through a combination of revenue generation from product sales, grant funding and the ongoing support of institutional shareholders. This assessment is based on current forecasts of cash flows, liquidity position, and the status of ongoing funding opportunities. Accordingly, these financial statements have been prepared on a going concern basis. The Directors have not identified any material uncertainties that may cast significant doubt on the Company's ability to continue as a going concern.
2.3. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
Sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.
Rendering of services
Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
2.4. Tangible Fixed Assets and Depreciation
Tangible fixed assets are stated at historical cost less depreciation. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Laboratory & Office Equipment 20% straight line
2.5. Leasing and Hire Purchase Contracts
Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged to income statement as incurred.
2.6. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the statement of financial position date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
Page 3
Page 4
2.7. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.
2.8. Pensions
The company operates a defined pension contribution scheme. Contributions are charged to the income statement as they become payable in accordance with the rules of the scheme.
2.9. Research and Development Costs
Research expenditure is written off to the income statement in the year in which it is incurred.
Development expenditure is written off in the same way unless the directors are satisfied as to the technical, commercial and financial viability of individual projects. In this situation, the expenditure is deferred and amortised over the period during which the company is expected to benefit.
No development expenditure has yet met the criteria for capitalisation.
2.10. Registrar Filing Requirements
The company has taken advantage of Companies Act 2006 section 444(1) and opted not to file the income statement, directors report, and notes to the financial statements relating to the income statement.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 12 (2025: 10)
12 10
4. Tangible Assets
Laboratory & Office Equipment
£
Cost
As at 1 April 2025 77,142
Additions 1,075
Disposals (833 )
As at 31 March 2026 77,384
...CONTINUED
Page 4
Page 5
Depreciation
As at 1 April 2025 31,850
Provided during the period 15,239
As at 31 March 2026 47,089
Net Book Value
As at 31 March 2026 30,295
As at 1 April 2025 45,292
5. Debtors
2026 2025
£ £
Due within one year
Trade debtors 1 4,372
Prepayments and accrued income 251,505 238,463
Other debtors 10,944 29,945
Corporation tax recoverable assets 102,426 144,722
VAT 19,752 36,309
384,628 453,811
6. Creditors: Amounts Falling Due Within One Year
2026 2025
£ £
Trade creditors 139,055 151,524
Other taxes and social security 36,239 20,717
Other creditors 3,565 4,094
Accruals and deferred income 82,937 80,132
261,796 256,467
7. Creditors: Amounts Falling Due After More Than One Year
2026 2025
£ £
Other loans 1,049,654 -
Convertible Loan Notes - £1,049,654
8. Share Capital
2026 2025
£ £
Allotted, Called up and fully paid 7,573 7,573
Page 5
Page 6
9. Financial Instruments
Convertible loan notes whose conversion terms contain variable settlement elements are classified as non-basic financial liabilities in accordance with FRS 102 Section 11/12. These liabilities are initially and subsequently measured at fair value through profit or loss. Changes in fair value are recognised in profit or loss within finance costs.
Finance Costs Breakdown Amount: 
Convertible loan note contractual interest: £33,025  (Accrued 10% coupon)
Fair value loss on financial instruments: £16,629 (FVTPL measurement adjustment)
Total Finance Costs / Interest Payable: £49,654 (Total statutory P&L charge)
10. Other Commitments
The total of future minimum lease payments under non-cancellable operating leases are as following:
2026 2025
£ £
Not later than one year 119,888 94,095
Later than one year and not later than five years 155,216 -
275,104 94,095
11. Related Party Transactions
During the year, the Company incurred consultancy fees of £6,000 in respect of services provided by Nick Claxton, a director. At 31 March 2026, the full amount remained outstanding. The Company and Mr Claxton intend to settle this balance through the grant of share options on a future fundraising. At 31 March 2026, the terms of any option grant had not been agreed and no options had been granted.
During the year, the Company issued £20,000 of convertible loan notes to Elaine Warburton OBE, who was a director until 31 March 2026. The notes were issued on the same terms as those subscribed for by other noteholders. The principal remained outstanding at 31 March 2026 and is included within the convertible loan note liability disclosed in note 7.
Page 6